Ogese, Monday O 
ORCID: 0000-0002-1873-4032, Lister, Adam, Farrell, Liam, Gardner, Joshua, Kafu, Laila, Ali, Serat-E, Gibson, Andrew, Hillegas, Aimee, Meng, Xiaoli ORCID: 0000-0002-7774-2075, Pirmohamed, Munir ORCID: 0000-0002-7534-7266 et al (show 3 more authors)
(2023)
A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment.
TOXICOLOGICAL SCIENCES, 197 (1).
pp. 38-52.
|
PDF
Ogese et al., 2023.pdf - Author Accepted Manuscript Download (2MB) | Preview |
Abstract
In vitro preclinical drug-induced liver injury (DILI) risk assessment relies largely on the use of hepatocytes to measure drug-specific changes in cell function or viability. Unfortunately, this does not provide indications toward the immunogenicity of drugs and/or the likelihood of idiosyncratic reactions in the clinic. This is because the molecular initiating event in immune DILI is an interaction of the drug-derived antigen with MHC proteins and the T-cell receptor. This study utilized immune cells from drug-naïve donors, recently established immune cell coculture systems and blinded compounds with and without DILI liabilities to determine whether these new methods offer an improvement over established assessment methods for the prediction of immune-mediated DILI. Ten blinded test compounds (6 with known DILI liabilities; 4 with lower DILI liabilities) and 5 training compounds, with known T-cell-mediated immune reactions in patients, were investigated. Naïve T-cells were activated with 4/5 of the training compounds (nitroso sulfamethoxazole, vancomycin, Bandrowski's base, and carbamazepine) and clones derived from the priming assays were activated with drug in a dose-dependent manner. The test compounds with DILI liabilities did not stimulate T-cell proliferative responses during dendritic cell-T-cell coculture; however, CD4+ clones displaying reactivity were detected toward 2 compounds (ciprofloxacin and erythromycin) with known liabilities. Drug-responsive T-cells were not detected with the compounds with lower DILI liabilities. This study provides compelling evidence that assessment of intrinsic drug immunogenicity, although complex, can provide valuable information regarding immune liabilities of some compounds prior to clinical studies or when immune reactions are observed in patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | adverse drug reaction, drug safety assessment, immunogenicity, liver, T-lymphocytes |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 20 Dec 2023 10:16 |
| Last Modified: | 05 Jan 2024 10:33 |
| DOI: | 10.1093/toxsci/kfad101 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3177548 |
Dimensions
Dimensions
